These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 38406596)

  • 1. Effectiveness of immune checkpoint inhibitors in combination with tyrosine kinase inhibitors in patients with advanced or metastatic colorectal carcinoma with either mismatch repair proficient or metastatic microsatellite stable disease: A systematic review and meta‑analysis.
    Li J; Zhu JX; Zhang YX; Li SQ
    Oncol Lett; 2024 Apr; 27(4):153. PubMed ID: 38406596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients.
    Wu Q; Wang Z; Luo Y; Xie X
    BMC Immunol; 2023 Sep; 24(1):27. PubMed ID: 37658314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.
    Ma S; Chen R; Duan L; Li C; Yang T; Wang J; Zhao D
    J Gastrointest Oncol; 2023 Apr; 14(2):1052-1063. PubMed ID: 37201046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the efficiency of immune checkpoint inhibitors for metastatic pMMR/MSS colorectal cancer: Options and strategies.
    Yang C; Zhao L; Lin Y; Wang S; Ye Y; Shen Z
    Crit Rev Oncol Hematol; 2023 Nov; 200():104204. PubMed ID: 37984588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer.
    Ding Y; Weng S; Zhu N; Mi M; Xu Z; Zhong L; Yuan Y
    Heliyon; 2023 Nov; 9(11):e22092. PubMed ID: 38058653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of radiotherapy combined with anti-angiogenic therapy and immune checkpoint inhibitors in MSS/pMMR metastatic colorectal cancer.
    Zhai M; Zhang Z; Wang H; Ren J; Zhang S; Li M; Liu L; Li L; Zhang L; Li X; Zhang T; Lin Z
    Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38112050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
    Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F
    Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial.
    Dong Q; Diao Y; Sun X; Zhou Y; Ran J; Zhang J
    BMJ Open; 2022 Apr; 12(4):e049992. PubMed ID: 35379611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of immune checkpoint inhibitors in colorectal cancer.
    Wang L; Huang C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?
    Matteucci L; Bittoni A; Gallo G; Ridolfi L; Passardi A
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma.
    San-Román-Gil M; Torres-Jiménez J; Pozas J; Esteban-Villarrubia J; Albarrán-Fernández V; Álvarez-Ballesteros P; Chamorro-Pérez J; Rosero-Rodríguez D; Orejana-Martín I; Martínez-Delfrade Í; Reguera-Puertas P; Fuentes-Mateos R; Ferreiro-Monteagudo R
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Tan Z; Zhang J; Xu L; Wang H; Mao X; Zou R; Wang Q; Han Z; Di Z; Wu D
    PLoS One; 2023; 18(10):e0290644. PubMed ID: 37844117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors for patients with microsatellite instability-high colorectal cancer: protocol of a pooled analysis of clinical trials.
    Tang X; Xu X; Chen R; Zhang M; Mei Z; Zhang S
    Front Oncol; 2023; 13():1331937. PubMed ID: 38234398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study.
    Li J; Cong L; Liu J; Peng L; Wang J; Feng A; Yue J; Li L; Wang X; Wang X
    Front Oncol; 2020; 10():594125. PubMed ID: 33282742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
    Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
    J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
    [No Abstract]   [Full Text] [Related]  

  • 16. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation.
    Wang Q; Shen X; Chen G; Du J
    Int J Cancer; 2023 Aug; 153(4):709-722. PubMed ID: 36752642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Efficacy of Immune Checkpoint Inhibitors for Patients with Advanced or Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Pyo J; Park HJ
    J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34441895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis.
    Li Y; Du Y; Xue C; Wu P; Du N; Zhu G; Xu H; Zhu Z
    BMC Gastroenterol; 2022 Oct; 22(1):431. PubMed ID: 36217119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Wang Y; Chen D; Pan Y; Li H; Zhao W; Lu T; Kong W; Ding M; Wang X; Zhang G
    Rev Med Virol; 2024 Jan; 34(1):e2495. PubMed ID: 38017632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer.
    An TQ; Qiu H; Zhou QB; Zong H; Hu S; Lian YG; Zhao RH
    World J Gastrointest Oncol; 2024 Jun; 16(6):2449-2462. PubMed ID: 38994132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.